ABSTRACT Deoxynivalenol (DON), which is a Type B trichothecene mycotoxin produced by Fusarium, frequently contaminates cereal staples, such as wheat, barley and corn. DON threatens animal and human health by suppressing food intake and impairing growth. While anorexia induction in mice exposed to DON has been linked to the elevation of the satiety hormones cholecystokinin and peptide YY 3-36 in plasma, the effects of DON on the release of other satiety hormones, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), have not been established. The purpose of this study was to determine the roles of GLP-1 and GIP in DON-induced anorexia. In a nocturnal mouse food consumption model, the elevation of plasma GLP-1 and GIP concentrations markedly corresponded to anorexia induction by DON. Pretreatment with the GLP-1 receptor antagonist Exendin 9-39 induced a dose-dependent attenuation of both GLP-1-and DON-induced anorexia. In contrast, the GIP receptor antagonist Pro 3 GIP induced a dose-dependent attenuation of both GIP-and DONinduced anorexia. Taken together, these results suggest that GLP-1 and GIP play instrumental roles in anorexia induction following oral exposure to DON, and the effect of GLP-1 is more potent and long-acting than that of GIP.
researchers first reported that exposure to DON at a dose of 2.5 mg/kg of body weight (bw) significantly increased indoleamine, serotonin (5-HT) and 5-hydroxyindole-3-acetic acid levels in the rat cerebellum and hypothalamus 24 h after oral administration (Fitzpatrick et al., 1988a,b) . Subsequent studies reported consistent findings, demonstrating that aminergic neurotransmitters and NUCB2/nesfatin-1 neurons in the hypothalamus mediate DONinduced feed refusal in pigs (Gaige et al., 2013; Prelusky et al., 1992) . In addition, oral administration of DON strongly increased proopiomelanocortin (POMC), melanocortin 4 receptor (MC4R) and amphetamine-regulated transcript mRNA expression in mice (Girardet et al., 2011) . Recently, Tominaga et al. (2016) showed that a change in the hypothalamic mRNA levels of proinflammatory cytokines and the activation of nuclear factor-kappa B could mediate DON-induced anorexia.
Food intake is also controlled by peripheral factors. The gastrointestinal (GI) system is known as the other core of appetite regulation. DON has been shown to induce the release of the gut satiety hormones cholecystokinin (CCK) and peptide YY ) (Flannery et al., 2012; Wu et al., 2013 Wu et al., , 2014b ). Accordingly, the mRNA level of CCK also increased in the small intestine after 3 h of DON exposure (Tominaga et al., 2016) . However, the mechanism by which DON affects the GI tract is not fully known. In addition, it remains unknown whether other hormones released from enteroendocrine cells, such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), are involved in this process (Cummings and Overduin, 2007) .
GLP-1 is a peptide cleaved from proglucagon. GLP-1 is produced primarily by enteroendocrine L cells in the distal ileum and colon. Both peripheral and central administration of GLP-1 to animals decrease food intake (Melvin et al., 2016; Seo et al., 2008; Turton et al., 1996; Williams et al., 2006) . Another hormone worthy to research is GIP, which is a 42-amino acid peptide that is present within and released from duodenal and jejunal enteroendocrine K cells in the proximal small bowel. GIP increases in humans after a mixed meal (Stock et al., 2005) . Both GLP-1 and GIP are widely considered to be satiety hormones that respond to energy balance, and these hormones accentuate glucosedependent insulin secretion and inhibit glucagon secretion from pancreatic b-cells (Dailey and Moran, 2013; Drucker, 2006; Skow et al., 2016) .
The goal of this study was to test the hypothesis that DON induces the release of the satiety hormones GLP-1 and GIP in mice and to determine the role of these hormones in the anorectic effect of DON. Here, we employed a widely used murine anorexia model (Flannery et al., 2011) to relate GLP-1 and GIP plasma concentrations to DON-induced food refusal. The results demonstrate that GLP-1 is a major contributor to the induction of anorexia after oral exposure to DON, whereas GIP may play a less important role in this response.
MATERIALS AND METHODS
Animals. Female B6C3F1 mice (9-11 weeks) were purchased from the Comparative Medicine Center of Yangzhou University and allowed to acclimate for a minimum of 1 week prior to the initial experiment. During acclimation, the mice were individually housed in plastic 'tub' cages (28.5 Â 17.8 Â 15 cm) with a stainless-steel grid lid, and wood shavings were scattered on the bottom of the cage (Bachmanov et al., 2002) . The room was maintained at 21-24 C and 40%-55% relative humidity on a 12-h light/dark cycle, with the lights turned on at 6 a.m. The mice were fed a high-fat diet (45% kcal from fat; Research Diets, Inc., Jiangsu Medicine Company, Jiangsu Province, MD12032). The experimental procedures for animal treatment were developed according to the Nanjing Agricultural University Committee on Animal Use and Care. All efforts were made to minimize the number of animals used in the study and their suffering.
Toxin and drugs. DON was purchased from Sigma-Aldrich (St. Louis, Missouri) and then dissolved in 100 ll of filter-sterilized PBS at doses of 0.5, 1.0, or 2.5 mg/kg bw. GLP-1 (Sigma-Aldrich, St. Louis, MO) and GIP (1-42, hydroxylated; ANASPEC, Fremont, California, USA) were prepared in PBS to provide an intraperitoneal (IP) injection at doses of 0.1 and 0.125 mg/kg bw, respectively. The GLP-1 receptor antagonist Exendin 9-39 (SigmaAldrich, St. Louis, MO) (Kofod et al., 1996) and the GIP receptor antagonist Pro 3 GIP (ANASPEC, Fremont, CA) were dissolved in 100 ll of sterile PBS at doses of 0.1 or 0.12 mg/kg bw. The antagonist doses were chosen based on the efficacies demonstrated in previous investigations of these receptors Parker et al., 2007; Williams et al., 2009) .
DON-induced plasma hormone measurement. For preliminary studies, the mice (3 mice/group) were orally gavaged with 0.5, 1.0, or 2.5 mg/kg bw of DON. Blood (1ml) was collected from the posterior vena cava into EDTA-coated tubes 0.5 and 6 h after exposure and then used to measure the hormones. To relate the doseresponse and kinetics of DON-induced elevation of GLP-1 and GIP, the mice (6 mice/group) were orally gavaged with 1.0 or 2.5 mg/kg bw of DON. Blood was collected into EDTA-coated tubes 0.5, 1, 2, and 6 h after exposure and then used to measure hormone levels. The control group was given PBS and blood was collected at the same time points, which were chosen based on data reported by Flannery et al. (2011) . For both experiments, the mice were fasted from 10:00 to 18:00 h but allowed free access to water before DON administration. The mice were euthanized with ether (in the air) before blood collection. Plasma was separated by centrifugation at 3000 Â g for 10 min at 4 C and then frozen in aliquots at À80 C until the hormone analysis.
Plasma levels of the hormones GLP-1 and GIP were measured using enzyme immunoassay kits for GLP-1 and GIP (Millipore, St Louis, Missouri). The plate absorbance was read at 450 nm using an ELISA plate reader.
DON and hormone exposure rapidly induces anorexia. The general experimental design for this study was based on Wu et al. (2014b) . On the day of the experiment, groups of mice (n ¼ 5) were fasted from 10:00 to 18:00 h but allowed free access to water. The mice were injected IP with 0, 1.0, or 2.5 mg/kg bw of DON, and their food intake was measured under red light conditions during the dark cycle at 0.5, 1, 2, 3, and 6h postexposure. To assess hormoneinduced anorexia, food intake was measured at the same time points after the administration of 0.1 and 0.125 mg/kg bw of GLP-1 and GIP. The doses were chosen based on the robust efficacies demonstrated in prior reports Neary et al., 2005; Williams et al., 2009) . The measurement times were based on reports that the anorectic effects of GLP-1 last longer than those of GIP (Holst, 2007) .The control groups were gavaged with PBS.
Receptor antagonists effect on hormone-and DON-induced anorexia. The general design for the receptor antagonist experiments was identical to that used for the anorexia models, except the mice were pretreated with the antagonist 30 min before DON exposure. To establish that the GLP-1 receptor antagonist Exendin 9-points as those used for the antagonist's effect on GLP-1-and GIP-induced anorexia.
Statistics. The data were analyzed using Sigma Plot 11.0 (Jandel Scientific; San Rafael, California, USA). Differences between means were considered to be statistically significant at p < .05. To determine statistical significance for multiple groups, 1-way ANOVA with the Holm-Sidak multiple comparisons test (Aickin and Gensler, 1996) was used. Two-way repeated ANOVA (1-factor) with the Holm-Sidak Method was used to analyze significant differences in food consumption in comparison to the control over time. A 2-way ANOVA with the Holm-Sidak Method was used to assess significant differences in plasma GLP-1 and GIP concentrations over time.
RESULTS
Exposure to DON by oral gavage at 1.0 or 2.5 mg/kg bw markedly increased plasma GLP-1 and GIP after 0.5 h but this increase was not evident after 6 h (Figs. 1 and 2). Based on this observation, the kinetics of the responses to these 2 doses were further investigated. At 1.0 mg/kg bw of DON, the plasma GLP-1 concentration were 2.9-, 2.9-, and 2.0-fold higher than those of the control after 0.5, 1, and 2 h, respectively; and the GLP-1 concentration returned to control concentration by 6 h. Following exposure to 2.5 mg/kg bw DON, the plasma GLP-1 concentration remained elevated (1.9-fold) after 6 h compared with the control, but the difference was not significant (Figure 3 ). Plasma GIP increased rapidly in response to both 1.0 and 2.5 mg/kg bw of DON within 1 h (Figure 4) . At 1.0 mg/kg bw of DON, plasma GIP concentration were 2.5-and 2.7-fold higher than the control concentration after 0.5 and 1 h, respectively. At 2.5 mg/kg bw of DON, plasma GIP concentration increased 2.7-and 2.9-fold after 0.5 and 1 h but returned to control concentration by 2 h. Finally, for both hormones, vehicle treatment had no effect after 0.5, 1, 2, and 6 h, suggesting that the initial induction during the first 6 h was not related to handling or the gavage procedure ( Fig. 3 and 4) .
Acute IP exposure of mice to 1.0 or 2.5 mg/kg bw doses of DON caused a significant reduction in food intake after 0.5, 1, 2, and 3 h compared with that of the control, but there was no effect on feed consumption at 6 h ( Figure 5 ). Mice were treated with exogenous GLP-1 and GIP to confirm that these hormones led to food refusal in this mouse model. GLP-1 significantly reduced food intake by 48%, 49%, 40%, and 48% relative to the control after 0.5, 1, 2, and 3 h, respectively ( Figure 6 ). Relative to the control, GIP significantly reduced food intake within 2 h (Figure 7) .
The receptor antagonists Exendin 9-39 and Pro 3 GIP had no effect on food intake at various time points relative to that of the control group (Figs. 8 and 9 ). GLP-1 and DON decreased food intake relative to the control after 0.5, 1, 2, and 3 h. These effects were attenuated with Exendin 9-39 after 0.5 h (Figure 8 ). Mice that were treated with Pro 3 GIP prior to GIP consumed 54% more food after GIP administration 0.5 h than mice treated with GIP alone. Moreover, mice treated with Pro 3 GIP prior to DON exposure consumed 65% more food after DON administration 0.5 h than mice exposed to DON alone (Figure 9 ) DISCUSSION Anorexia and concomitant growth suppression induced by DON have long been major concerns for human and animal health; however, the mechanism that underlies these effects has not been fully elucidated. The in vivo results presented herein indicate, for the first time, that DON increases the plasma concentrations of GLP-1 and GIP. Additionally, the observed DONinduced increase was inhibited by the GLP-1 receptor antagonist Exendin 9-39 and the GIP antagonist Pro 3 GIP, confirming the roles of these peptides in DON-induced anorexia. Therefore, both peptides may contribute to DON-induced anorexia in mice.
Consistent with our results, the concentrations of these gutderived hormones dramatically increase within 15 min in response to a meal (Dailey and Moran, 2013) . The same change was observed when DON was administered to fasted mice. Anorexia induced by DON or other trichothecenes typically occurs within 30 min (Flannery et al., 2011; Wu et al., 2014a Wu et al., , 2015 . This anorectic effect could be attributed to the rapid increase of GLP-1 and GIP concentrations in the plasma. It was not surprising that the GIP concentrations in the plasma were only increased 1 h after exposure to DON and that the observed effect was remarkably less persistent than that of GLP-1 because GIP is secreted from the upper small intestine and GLP-1 is secreted primarily from the lower small intestine, where the density of L cells is higher (Cummings and Overduin, 2007; Holst, 2007) ; the L-cell numbers in the proximal gut are sufficient to trigger an early elevation of GLP-1 in the bloodstream (Theodorakis et al., 2006) .
It is well known that GLP-1 reduces food consumption by eliciting satiety signals via the vagal afferents (Kanoski et al., 2011) or via blood perfusion into the hypothalamus in response to overconsumption. In addition, GLP-1 attenuates appetite by decreasing gastric emptying and intestinal motility (Dailey and Moran, 2013) , which is directly and indirectly mediated by the CNS induction of c-fos immunoreactivity (van Bloemendaal et al., 2014) . Further, GLP-1 enhances glucose-induced insulin secretion and suppresses glucagon release, which also appears to contribute to the satiety response (Steinert et al., 2016) . Here, we observed that DON significantly increased the plasma GLP-1 concentrations compared with the control values within 2 h at both 1.0 and 2.5 mg/kg bw. Therefore, the GLP-1 response in DON-exposed mice was far greater than that reported previously after meal consumption (Baggio and Drucker, 2007) . Recent investigations in the murine STC-1 model suggested that DON induces the secretion of GLP-1 through the calcium- sensing receptor (CaSR) and the transient receptor potential ankyrin-1 channel (TRPA1) . Although the manner by which DON is chemically recognized by enteroendocrine cells is not fully understood, normal physiologic processes, such as the homeostasis of gut hormone release, are likely disturbed.
GLP-1 could act by binding to the GLP-1 receptor located on the vagal afferents or several regions of the CNS, including the hypothalamus, the area postrema (AP) and the nucleus tractus solitarii (NTS) (Baggio and Drucker, 2007; Merchenthaler et al., 1999) . The AP and the NTS in the brainstem convey peripheral signals, such as hormone signals and vagal afferent activation, to the arcuate nucleus (ARC) of the hypothalamus (Bailey, 2008) . The ARC regulates energy balance, increasing the expression of anorexigenic peptides (POMC) and decreasing orexigenic signaling peptides (neuropeptide Y and agouti-related peptide) (van Bloemendaal et al., 2014) . Moreover, GLP-1R is also expressed in the intestine, and acute IP administration of GLP-1 resulted in the dose-dependent inhibition of food intake in rodents (Abbott et al., 2005) . We demonstrated here that exogenous GLP-1 induced anorexia, which could be inhibited by a potent and specific antagonist, Exendin 9-39 (Thorens et al., 1993) . These findings suggest that in this mouse anorexia model, GLP-1R mediates both GLP-1-and DON-induced food refusals.
GIP is another predominant incretin hormone that responds to nutrient ingestion (Baggio and Drucker, 2007; Seino and Yabe, 2013) . Of note, the results obtained in this study differed from those reported in a previous study (Flannery et al., 2011) that declared that plasma GIP had no effect on IP exposure to DON in the same mouse model. However, there are 2 crucial explanations for the conflicting results. First, the administration of DON differed between the 2 studies; administering DON via oral gavage better imitates the physiological process of feeding. With this administration route, DON acts through the GI tract and has more time to interact with GI endocrine cells, especially duodenal K cells, rather than going directly into the abdominal cavity. Second, the measurement approaches differed in the 2 studies. GIP was measured individually using enzyme immunoassay kits in our study but was measured with a milliplex map kit in the other study.
Unlike GLP-1, the effect of GIP on appetite and feeding behavior is controversial. Stock et al. (2005) reported that GIP Figure 8 . Effect of Exendin 9-39 on GLP-1-and DON-induced anorexic response. Mice were pretreated with 0.1 mg/kg bw Exendin 9-39 or PBS and 30 min later treated with 0.1 mg/kg bw GLP-1 or 1.0 mg/kg bw DON. Food intake was then measured at various intervals. Data are shown as the mean 6 SEM (n ¼ 5/gp). * indicates a statistically significant difference between the GIP treatment group and the control group at that time point (p < .05). levels increased in humans after a mixed meal. However, Edholm et al. (2010) found that GIP did not affect satiety or gastric emptying in humans. Interestingly, in this study, we found that exogenous GIP triggered food refusal. GIP may be able to stimulate GLP-1 secretion from the L-cell model (Roberge and Brubaker, 1993) and could then indirectly reduce food intake (Wewer Albrechtsen et al., 2016) .
Similar to the GLP-1R, the GIP receptor is a member of the 7-transmembrane-spanning, heterotrimeric G-protein-coupled receptor superfamily (Usdin et al., 1993) and is expressed in many peripheral organs, including the pancreas, stomach, small intestine, adipose tissue and several CNS regions (Baggio and Drucker, 2007) . Subsequently, we observed that exogenous GIP-or DON-induced anorexia could be inhibited by the GIP receptor antagonist Pro 3 GIP (Gault et al., 2002) . Therefore, GIPR plays an indispensable role in DON-induced anorexia. However, the exact mechanism associated with this role is unknown. Future studies should investigate how DON induces GIP release and determine whether the involved mechanism is analogous to the suppression of glucose absorption by inhibiting intestinal motility in a somatostatin-mediated pathway or through a GLP-1-mediated pathway (Ogawa et al., 2011) . In summary, the data provided herein suggest that DONinduced anorexia is consistent with plasma GLP-1 and GIP elevation, activating both GLP-1R and GIPR (Figure 10) . Given that previous studies demonstrated that DON alters the endocrine/ brain systems through the release of proinflammatory cytokines and anorexigenic hormones, such as CCK and PYY significant difference between the GIP treatment group and the control group at that time point (p < .05). (Flannery et al., 2012; Maresca, 2013; Wu et al., 2013 Wu et al., , 2014b , future studies should focus on how DON causes the coexpression of gut enteroendocrine cell (EEC) hormones, resulting in appetite signaling via the peripheral nervous system and the CNS. 
